Recon: J&J reports lung cancer therapy significantly prolonged survival in study; Stryker to buy Inari Medical for $4.9B
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- Generic GLP-1 drugs could help Medicare drive a harder bargain for Ozempic and Wegovy (STAT)
- Wegovy and Zepbound tipped to fuel $20B boom in heart failure market (Fierce Pharma)
- Johnson & Johnson says its lung cancer drug significantly extended survival (STAT) (Reuters)
- These common medications could be releasing ‘forever chemicals’ into the environment (The Washington Post)
- Google’s secretive anti-aging company Calico finally released data. Its drug failed (STAT)
- After tough year, Moderna CEO confronts challenges for RSV, COVID businesses in shareholder letter (Fierce Pharma)
- Device maker Stryker strikes $4.9 billion deal for Inari Medical (Reuters)
- AbbVie cuts 2024 profit forecast on acquisition expenses (Reuters)
- Anthem Biosciences eyes $397M public offering in India (Endpoints)
- France identifies first case of new mpox variant, AFP reports (Reuters)
- Medtechs Ponder Significance Of UK’s Elective Reform Plan (MedTech Insight)
- China Greenlights First Stem Cell Therapy On Mixed Clinical Findings (Pink Sheet)
- Japan’s 2025 ‘Off-Year’ Price Cut Stirs Deeper Concerns (Pink Sheet)
- Spanish Health Ministry Targets Efficiency With New Medicine Pricing Rules (Pink Sheet)
- Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty (BioSpace)
- Bird flu risk remains low after first US death, WHO says (Reuters)
- Can an epilepsy drug do more than reduce seizures? (STAT)
- Four years after AlphaFold’s AI ‘solved’ protein structure, a fierce competition lives on (STAT)
- Metsera’s long-acting GLP-1 looks competitive in Phase 2 obesity study (Endpoints)
- Immuneering touts positive pancreatic cancer data for MEK inhibitor (Endpoints)
- Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia as it looks beyond Casgevy (Endpoints)
- BWX Technologies to buy Canadian isotope maker for $525M (Endpoints)
- Pfizer extends AI drug discovery pact with PostEra, adding ADCs to deal (Endpoints)
- Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans (Endpoints)
- Avenzo picks up another ADC, this time with multi-partnered DualityBio (Endpoints)
- XyloCor raises $67.5M Series B, updates pivotal gene therapy trial plans (Endpoints)
- Bausch + Lomb re-ups 'Faces of Glaucoma' campaign to raise awareness of the eye disease (Fierce Pharma)
- With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi (Fierce Pharma)
- Klick Health swoops in to acquire life sci market access agency Peregrine (Fierce Pharma)
- Wearable maker ActiGraph acquires assets from Biofourmis to boost clinical trial offerings (STAT)
- Philips sells small chipmaking subsidiary, Telegraaf reports (Reuters)
- Outset Medical to pay down debt after raising nearly $300M (MedTech Dive)
- The long history of distrust for American insurance companies (STAT)
- AI Adoption In Pathology Is Lagging: Funding And Clinical Standardization Needed (MedTech Insight)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
